Search:
		Update on Natalizumab Sponsored by the Postgraduate Institute for Medicine Release date: January 2006 Expiration date: January 2007 Estimated time to complete activity: 1 hour This educational program is supported through an educational grant from Biogen Idec and Elan Pharmaceuticals. Important recent data (two-year follow up from the AFFIRM trial, presented at AAN; two-year follow up from the SENTINEL trial, presented at ECTRIMS) has emerged on the safety and efficacy of natalizumab, but this data may have been overlooked following the voluntary suspension of natalizumab in February, 2005. This suspension was in response to reports of the development of progressive multifocal leukoencephalopathy (PML) in three patients taking natalizumab and additional immunosuppressants. This program will provide a review of PML and its relationship both to MS and to immunosuppressant therapies. A discussion by the participants on their current view of natalizumab and targeted antibody immunotherapies in general, will follow along with a discussion of the screenings and safeguards necessary should natalizumab return to market. Windows Me / XP / 2000. 800 MHz P3 processor. 256 MB RAM. Microsoft Internet Explorer (6.0 or higher). 16-bit sound card and Windows Media Player (9.0 or greater). Video Card capable of 16-bit color. Adobe Acrobat 6.0 or greater. Click here to review the complete CME information.
	Resources  |  About Us  |  Contact Us  |  Privacy Policy  |  Disclaimer  |  Editorial & Sponsorship Policy  |  Terms of Use Search: